Nkarta News

Needham: Reiterates the Nkarta (NKTX.US) rating and adjusted from buy to buy rating, target price is $15.00.

Zhitong FinanceApr 10 19:41

Nkarta Analyst Ratings

BenzingaApr 10 19:31

Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)

TipRanksApr 10 19:00

TD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)

TipRanksMar 26 19:25

Nkarta Analyst Ratings

BenzingaMar 26 00:33

Needham Reiterates Buy on Nkarta, Maintains $15 Price Target

BenzingaMar 22 19:49

Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Dianthus Therapeutics (DNTH) and Eli Lilly & Co (LLY)

TipRanksMar 22 19:10

Nkarta's Strategic Pivot to NKX019 Spurs Buy Rating Amid Strong Financials and Promising Trial Prospects

TipRanksMar 22 18:45

Buy Rating for Nkarta: Promising Future for NKX019 in Autoimmune Disease Treatment

TipRanksMar 22 18:26

Nkarta's Strategic Focus and Financial Strength Underpin Buy Rating

TipRanksMar 22 18:27

Nkarta Analyst Ratings

BenzingaMar 22 17:47

Raymond James Downgrades Nkarta to Outperform, Raises Price Target to $16

BenzingaMar 22 17:48

Innovative NK-Cell Therapy: A Buy Rating for Nkarta's Groundbreaking Approach to Autoimmune Diseases

TipRanksMar 19 13:38

Nkarta Analyst Ratings

BenzingaMar 5 21:57

Mizuho Maintains Buy on Nkarta, Raises Price Target to $31

BenzingaMar 5 21:58

Mizuho Securities Adjusts Price Target on Nkarta to $31 From $9 as Lupus Nephritis Program Gets Attention, Keeps Buy Rating

MT NewswiresMar 4 23:03

Leerink Partners Keeps Their Buy Rating on Nkarta (NKTX)

TipRanksFeb 19 12:47

HC Wainwright & Co. Maintains Buy on Nkarta, Raises Price Target to $22

BenzingaJan 17 05:01

Nkarta Analyst Ratings

BenzingaJan 17 05:00

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Incyte (INCY) and Nkarta (NKTX)

TipRanksJan 11 14:31